Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

brenetafusp (IMC-F106C)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Immunocore

Drug class:

CD3 agonist, PRAME inhibitor

Related drugs:

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

linvoseltamab (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

MultiTAA T cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

›

PRAME expression	Ovarian Cancer	PRAME expression	Ovarian Cancer	IMC-F106C Sensitive: C3 – Early Trials IMC-F106C Sensitive : C3	IMC-F106C Sensitive: C3 – Early Trials IMC-F106C Sensitive : C3
PRAME expression	Non Small Cell Lung Cancer	PRAME expression	Non Small Cell Lung Cancer	IMC-F106C Sensitive: C3 – Early Trials IMC-F106C Sensitive : C3	IMC-F106C Sensitive: C3 – Early Trials IMC-F106C Sensitive : C3